Richard Klausner

Richard Klausner has filed 23 sales at Juno Therapeutics, Inc. and Lyell Immunopharma, Inc., worth EUR 6,549,298 with a median of EUR 191,477. The largest, all at Juno, are EUR 1,237,104 on December 21, 2017, EUR 863,064 on March 2, 2016 and EUR 606,898 on July 7, 2017. A single purchase is on file, EUR 87,459 at Lyell on March 14, 2025, which is 4% of the open-market trades.

Richard Klausner is a Director at Juno (31 filings) and at Lyell (4), and appears at Illumina, Inc. as Sr VP, Chief Medical Officer (1). The 36 filings were published from February 1, 2016 to March 18, 2025, with 9 grants and 3 filings of another nature.

Most of it dates from 2016 (11), 2017 (14) and 2018 (7); afterwards there is one filing each in 2021, 2022, 2023 and 2025. None falls in the last twelve months. Publication delay is a median of 2 days. Klausner has 15, 11 and 10 own market trades within 30 days of colleagues at Juno Therapeutics, Inc., in that order. All on the same side. Names in order: Steve Harr, Hans Edgar Bishop and Robert Azelby.